$ADGM News

Adagio Medical Announces Strategic Review Process to Maximize Shareholder Value

Adagio Medical's Board Completes Strategic Review And Has Initiated A Formal Process To Explore Alternatives To Maximize Shareholder Value; May Include Acquisition, Merger, Business Combination, Or Other Transaction

Adagio Medical Highlights First Patient Treated in IDE Study Evaluating Next-Generation vCLAS™ Ultra System for Ventricular Tachycardia at Banner – University Medical Center Phoenix

Adagio Medical Reports Second Quarter 2026 Results

Adagio Medical Holdings Q2 EPS $(0.30) Beats $(0.31) Estimate

Adagio Medical Stock Is Trending Overnight: Here's Why ADGM Jumped 22% After Hours

Adagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA System

Adagio Medical Treats First Patient With Its vCLAS Ultra Ultra-Low Temperature Ablation System Under FDA's Expanded Access Authorization

LUCID CAPITAL MARKETS Initiates Coverage On Adagio Medical Holdings with Buy Rating, Announces Price Target of $3

Adagio Medical Submits Premarket Approval Application to FDA for vCLAS® Ventricular Ablation System for the Treatment of Ventricular Tachycardia

Adagio Medical Submits PMA Application To FDA For vCLAS Ventricular Ablation System For Treatment Of Drug-Refractory, Recurrent, Sustained Monomorphic VT In Patients With Ischemic Or Non-Ischemic Structural Heart Disease

Adagio Medical Reports First Quarter 2026 Results and Meaningful Clinical Progress

Adagio Medical Holdings Q1 EPS $(0.31) Misses $(0.29) Estimate

Adagio Medical to Participate in the BofA Securities 2026 Health Care Conference

Adagio Medical Holdings shares are trading lower. The company presented six-month results from its FULCRUM-VT Investigational Device Exemption clinical trial.

Adagio Medical Holdings shares are trading lower. The company presented six-month results from its FULCRUM-VT Investigational Device Exemption clinical trial.

Adagio Medical Heart Ablation System Shows 84% Freedom From Shock

Reported Sunday, Adagio Medical's FULCRUM-VT Pivotal IDE Trial Meets Safety And Effectiveness Endpoints With 84% Freedom From Shock And 59% Freedom From VT Recurrence

Adagio Medical Announces Positive Pivotal Results for vCLAS® Ventricular Ablation System

Adagio Medical’s ULTA Technology to Be Featured at the Heart Rhythm 2026 Conference